Needham & Company Reiterates Hold Rating on Acadia Pharmaceuticals (ACAD), Sees 50% Chance of pimavanserin Approval in Alzheimer's
Tweet Send to a Friend
Needham & Company analyst Ami Fadia reiterated a Hold rating on Acadia Pharmaceuticals (NASDAQ: ACAD), following announcement that the FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
